All In Biotech

Drug Trial Radar · NCT06619236

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 584 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

584

Actual

Start

Feb 7, 2025

Primary completion

Aug 18, 2026

Study completion Oct 2027

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.

Conditions

  • Platinum-resistant Ovarian Cancer

Interventions

  • Rina-SDrug

    Intravenous (IV) infusion

  • PaclitaxelDrug

    IV infusion

  • TopotecanDrug

    IV infusion

  • Pegylated liposomal doxorubicin (PLD)Drug

    IV infusion

  • GemcitabineDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 1.5 years

Locations

177 sites in 18 countries. Site status is shown where the registry gives one.

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Arizona Center for Cancer Care (ACCC) - Biltmore

    Scottsdale, Arizona

  • University of Arizona Cancer Center - Research and Administration at Main Campus

    Tucson, Arizona

  • Providence Saint Joseph Medical Center - Roy and Patricia Disney Family Cancer Center

    Burbank, California

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • USCF Mission Bay

    San Francisco, California

  • Kaiser Permanente - Vallejo Medical Center

    Vallejo, California

  • UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center

    Aurora, Colorado

  • Hartford Hospital

    Hartford, Connecticut

  • Yale School of Medicine

    New Haven, Connecticut

  • Norwalk Hospital

    Norwalk, Connecticut

  • SCRI - Florida Cancer Specialists - South Region Research Office

    Fort Myers, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Orlando Health Cancer Institute - Downtown Orlando

    Orlando, Florida

  • Sarasota Memorial Hospital

    Sarasota, Florida

  • SCRI - Florida Cancer Specialists - West Palm Beach

    West Palm Beach, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Northside Hospital Atlanta

    Atlanta, Georgia

  • Augusta University Georgia Cancer Center

    Augusta, Georgia

  • Kapi'olani Medical Center for Women and Children

    Honolulu, Hawaii

  • Northwest Cancer Center - Dyer

    Dyer, Indiana

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • HCA Midwest Health

    Overland Park, Kansas

  • St. Elizabeth Healthcare - Edgewood

    Edgewood, Kentucky

  • Baptist Health Lexington

    Lexington, Kentucky

  • Louisiana State University Health Sciences Center (LSU Health) - New Orleans

    New Orleans, Louisiana

  • Trials365, LLC (Gynecologic Oncology Associates-Shreveport)

    Shreveport, Louisiana

  • Maine Medical Center Cancer Institute- Scarborough

    Scarborough, Maine

  • Holy Cross Health - Holy Cross Hospital

    Silver Spring, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Corewell Health (Spectrum Health)

    Grand Rapids, Michigan

  • Saint Joseph Mercy Ann Arbor Hospital

    Ypsilanti, Michigan

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Center of Hope

    Reno, Nevada

  • Holy Name Medical Center

    Teaneck, New Jersey

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Perlmutter Cancer Center - 38th Street

    New York, New York

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.